Followers | 198 |
Posts | 25027 |
Boards Moderated | 0 |
Alias Born | 04/03/2010 |
Monday, January 18, 2021 2:17:54 PM
It’s data. They are management. They have the right to review it. It is not “bad or good” necessarily, as we know companies apply and get approval sometime for what might on first glance be “bad data.” Persons like AF qualify these drugs, wrongly. All of that is the application of judgment. Companies have the right and ability to review the data fully before they characterize it... that can take longer than 4 days. Therefore receipt of data, does not trigger a 4 day rush to judgment.
If it operated the way people suggest it would be known as the “4 day rush to judgment rule”. It’s not that.
Should they disclose ASAP? Sure. Best practice and it avoids giving malcontents and evil doers opportunities and it helps avoid misstatements that can create liabilities.
Can they use an 8-K to disclose? Yes, it’s not just relevant to the required items but is permissive, so that when management makes its determinations, it can use that form.
The permissive and the required details appear to confuse investors into creating this axiom, but mostly with this company. It’s not an axiom I’ve seen with any other companies but most of the others do not have investors quite so desperate to make final conclusions from lack of disclosure. You can’t make a positive conclusion from a lack of disclosure. It’s not a rational result.
Articles on the subject dance around this point and clearly suggest that there is a problem with the disclosure rules, that other “rules” were created to address the issue loosely, but they are not effective at forcing rapid disclosure. And that is because of the sensitivities around trial data and the different approaches of the different regulators.
So it’s permissively allowed under the 8K rules, it is best practice to disclose ASAP once a company is satisfied with its analysis, but it is not immediately required. They can analyze so that they understand the full picture, but they might inadvertently create possible liability if they say anything or file anything that miscommunicates material facts relevant to the trial.
It is unlikely that a complex trial like this, with the blind data we have seen, would provide an unambiguously negative reading across the board, in my opinion, so the entire discussion is moot. It allows the people to imply they’ve disclosed by not disclosing...which is ridiculous, but takes the heat off, so I can imagine why the company seems happy with people thinking this... though what they’ve really said only is: 1) when we KNOW, we will disclose ASAP; and 2) if we knew it was a total failure, don’t you think we’d tell you quickly? That is a question, by the way...
It’s corporate speak for, I can’t tell you anything right now, but we’re doing our best and we will disclose ASAP and have shareholder’s interests in mind. But they are not really saying anything that we don’t already know.
IMHO, we all pretty much know the trial results are complex, there could be multiple areas of success and the picture could be mixed. But the blind data suggests very good results, which makes unambiguously “bad” results, whatever that means, unlikely. So trying to conclude that delay, is unambiguously good, is more about practical details than regulation.
Concluding we have “good results” is flawed if based upon a regulation that is not directly and clearly applicable, as an axiom. It’s also a kind of reasoning that is flawed as a form of deriving “knowledge” generally. It’s just poor logic.
But, for other reasons, practical reasons, reasons of trust, or considerations related to unblinded data and the confidence one might have unblinded data one might be fairly confident in the notion that delay is probably a positive, that the trial is probably not a TOTAL failure or they’d probably, though not certainly, have nothing to keep analyzing. But none of it is certain until you have the data.
And that is not a “short” position. That is just being fact driven. We will know more when we know. Some people may conclude it’s a good sign and buy more while they can. But no one knows for sure until we know. But creating an axiom from a rule that is not directly and clearly applicable (and even if it was) to determine a factual outcome is certain, is just not good logic. Maybe someone might claim it’s a short-hand but even then, not a very good one as it depends on a lot of unknowable factors.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM